BRCA2 and breast cancer: Accordingly, cells with impaired HR, for example those harboring pathogenic mutations in breast cancer genes BRCA1 or BRCA2, are hypersensitive to PARP inhibitors and persistently accumulate DSB due to the error-prone NHEJ [16].